Drug intelligence / Profile preview

MPL-009

Development stage: Unknown
Lead developer: MediPharm Labs
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

**MPL-009** is an investigational balanced cannabis herbal extract oil containing delta-9-tetrahydrocannabinol and cannabidiol in a 1:1 ratio. Each mL contains 25 mg cannabidiol and 25 mg delta-9-tetrahydrocannabinol. It is being evaluated by the University of Manitoba in the Phase 1/2 CAN-PONC trial as supportive symptom-management treatment for children with cancer, including relapsed or refractory malignancies. The study evaluates tolerability during dose escalation and maintenance treatment. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT05754840/))

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on MPL-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPL-009.

Explore the full profile